Abstract
A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is
| Original language | English |
|---|---|
| Pages (from-to) | 1382-1391 |
| Number of pages | 10 |
| Journal | Cancer Epidemiology Biomarkers and Prevention |
| Volume | 15 |
| Issue number | 7 |
| DOIs | |
| State | Published - Jul 2006 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Epidemiology
- Oncology
Cite this
Celecoxib treatment alters the gene expression profile of normal colonic mucosa. / Glebov, Oleg K.; Rodriguez, Luz M.; Lynch, Patrick; Patterson, Sherri; Lynch, Henry T.; Nakahara, Kenneth; Jenkins, Jean; Cliatt, Janet; Humbyrd, Casey Jo; DeNobile, John; Soballe, Peter; Gallinger, Steven; Buchbinder, Aby; Gordon, Gary; Hawk, Ernest; Kirsch, Ilan R.
In: Cancer Epidemiology Biomarkers and Prevention, Vol. 15, No. 7, 07.2006, p. 1382-1391.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Celecoxib treatment alters the gene expression profile of normal colonic mucosa
AU - Glebov, Oleg K.
AU - Rodriguez, Luz M.
AU - Lynch, Patrick
AU - Patterson, Sherri
AU - Lynch, Henry T.
AU - Nakahara, Kenneth
AU - Jenkins, Jean
AU - Cliatt, Janet
AU - Humbyrd, Casey Jo
AU - DeNobile, John
AU - Soballe, Peter
AU - Gallinger, Steven
AU - Buchbinder, Aby
AU - Gordon, Gary
AU - Hawk, Ernest
AU - Kirsch, Ilan R.
PY - 2006/7
Y1 - 2006/7
N2 - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is
AB - A clinical trial was recently conducted to evaluate the safety and efficacy of a selective inhibitor of cyclooxygenase-2 (celecoxib) in hereditary nonpolyposis colon cancer patients. In a randomized, placebo-controlled phase I/II multicenter trial, hereditary nonpolyposis colon cancer patients and gene carriers received either celecoxib at one of two doses or placebo. The goal was to evaluate the effects of these treatment arms on a number of endoscopic and tissue-based biomarker end points after 12 months of treatment. As part of this trial, we analyzed gene expression by cDNA array technology in normal descending (rectal) colonic mucosa of patients before and after treatment with celecoxib or placebo. We found that treatment of patients with celecoxib at recommended clinical doses (200 and 400 mg p.o. bid), in contrast to treatment with placebo, leads to changes in expression of >1,400 genes in the healthy colon, although in general, the magnitude of changes is
UR - http://www.scopus.com/inward/record.url?scp=33746411410&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=33746411410&partnerID=8YFLogxK
U2 - 10.1158/1055-9965.EPI-04-0866
DO - 10.1158/1055-9965.EPI-04-0866
M3 - Article
VL - 15
SP - 1382
EP - 1391
JO - Cancer Epidemiology Biomarkers and Prevention
JF - Cancer Epidemiology Biomarkers and Prevention
SN - 1055-9965
IS - 7
ER -